⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OCS News
Oculis Holding AG Ordinary shares
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
globenewswire.com
OCS
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
globenewswire.com
OCS
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
globenewswire.com
OCS
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
globenewswire.com
OCS
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
globenewswire.com
OCS
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
globenewswire.com
OCS
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
globenewswire.com
OCS
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
globenewswire.com
OCS
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
globenewswire.com
OCS
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
globenewswire.com
OCS